New drugs or alternative therapy to blurring the symptoms of fibromyalgia—a patent review

References

• Pergolizzi JV Jr, Raffa RB, Taylor R, et al. A review of duloxetine 60 mg once-daily dosing for the management of diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain due to chronic osteoarthritis pain and low back pain. PAIN Prat. 2013;13(3):239–252.
   PubMed Web of Science ®Google Scholar
• Nagakura Y. Challenges in drug discovery for overcoming ‘dysfunctional pain’: an emerging category of chronic pain. Expert Opin Drug Discov. 2015;10:1043–1045.
   PubMed Web of Science ®Google Scholar
• Christidis N, Ghafouri B, Larsson A, et al. Comparison of the levels of pro- inflammatory cytokines released in the vastus lateralis muscle of patients with fibromyalgia and healthy controls during contractions of the quadriceps muscle – a microdialysis study. PLoS One. 2015; 10(12):1–17.
   Web of Science ®Google Scholar
• Arnold LM, Gebke KB, Choy EHS. Fibromyalgia: management strategies for primary care providers. Int J Clin Pract. 2016 Feb;70(2):99–112.
   PubMed Web of Science ®Google Scholar
• De Santana JM, Ml K, Sluka KA. Animal models of fibromyalgia. Arthritis Res Ther. 2013;15(6):1–13.
   Web of Science ®Google Scholar
• Clauw DJ. Fibromyalgia a clinical review. JAMA. 2014;311(15):1547–1555.
   PubMed Web of Science ®Google Scholar
• Ramzy EA. Comparative efficacy of newer antidepressants in combination with pregabalin for fibromyalgia syndrome: a controlled, randomized study. Pain Practice. 2016. DOI:10.1111/papr.12409
   PubMed Web of Science ®Google Scholar
• Rehm SE, Koroschetz J, Gockel U, et al. Original article A cross-sectional survey of 3035 patients with fibromyalgia : subgroups of patients with typical comorbidities and sensory symptom profiles. Rheumatology. 2010;49(6):1146–1152.
   PubMed Web of Science ®Google Scholar
• Menzies V, Thacker LR, Mayer SD, et al. Polypharmacy, opioid use, and fibromyalgia: a secondary analysis of clinical trial data. Biol Res Nurs. 2016;19(1):97–105 Jul 18. pii: 1099800416657636.
   Web of Science ®Google Scholar
• Ablin J, Fitzcharles M-A, Buskila D, et al. Treatment of fibromyalgia syndrome: recommendations of recent evidence-based interdisciplinary guidelines with special emphasis on complementary and alternative therapies. Evid Based Complement Altern Med. 2013;2013:1–7.
   Google Scholar
• Traynor LM, Thiessen CN, Traynor AP. Pharmacotherapy of fibromyalgia. Am J Health Syst Pharm. 2011;68:1307–1319.
   PubMed Web of Science ®Google Scholar
• Nascimento SS, DeSantana JM, Nampo FK, et al. Efficacy and safety of medicinal plants or related natural products for fibromyalgia: a systematic review. Evid Based Complement Alternat Med. 2013;2013:1-10. 149468. DOI:10.1155/2013/149468.
   Web of Science ®Google Scholar
• Halland M, Talley NJ. New treatments for IBS. Nat Rev Gastroenterol Hepatol. 2013;10(1):13–23.
   PubMed Web of Science ®Google Scholar
• Hauser W, Walitt B, Fitzcharles M-A, et al. Review of pharmacological therapies in fibromyalgia syndrome. Arthritis Res Ther. 2014;16(1):201.
   PubMed Web of Science ®Google Scholar
• Choy E, Marshall D, Gabriel ZL, et al. A systematic review and mixed treatment comparison of the efficacy of pharmacological treatments for fibromyalgia. Semin Arthritis Rheum. 2011;41:335–345.
   PubMed Web of Science ®Google Scholar
• Farber L, Mueller W, Stratz T Method of treating fibromyalgia or associated functional symptoms of fibromyalgia. US0055176. 2010.
   Google Scholar
• Nagakura Y, Tsukamoto M, Watabiki T Therapeutic agent for fibromyalgia. WO 071136. 2011.
   Google Scholar
• Frosch S, Linz K (1r,4r)-6ʹ-Fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4ʹ,9ʹ-dihydro-3ʹH-spiro-[cyclohexane-1,1ʹ-pyrano[3,4,b]indol]-4-amine for Treating Fibromyalgia and Chronic Fatigue Syndrome. US 0202701. 2013.
   Google Scholar
• Chen CC, Lin YL, Fang JM, et al. Methods and compositions for treating pain. WO 120078. 2013.
   Google Scholar
• Yoshlda, C and Nakao K. Therapeutic agent or prophylactic agent for fibromyalgia. US20130190503 A1. 2013.
   Google Scholar
• Morita Y, Izumimoto N, Iseki K, et al. Cyclic amine derivative and use thereof for medical purposes. WO 2013147160. 2013.
   Google Scholar
• Nishimura Y, Ueda H Prophylactic or therapeutic agent for fibromyalgia. WO 088106. 2014.
   Google Scholar
• Ishihara T, Ikegai K, Kuriwaki I, et al. Benzothiophene compound. US20140364421 A1. 2014.
   Google Scholar
• Roberts SC Compositions and methods of treatment that include plant extracts. US 0269912 A1. 2012.
   Google Scholar
• Greve H Novel therapeutic concepts for treating fibromyalgia. EP 2432471 A1. 2012.
   Google Scholar
• Quintans-Júnior LJ Método de obtenção de complexos de inclusão de linalol, complexos de inclusão obtidos e seu uso no tratamento de dor. BR 102013030026-8 A2. 2013.
   Google Scholar
• Araújo AAS, Quintans-Júnior LJ, Nascimento SS, et al. Método de obtenção de complexos de inclusão de óleo essencial de ocimum basilicum, complexos de inclusão obtidos e seu uso no tratamento de dor. BR 1 O 2013 025677-3 A2. 2013.
   Google Scholar
• Zhang HY Orally-taken traditional Chinese medicine composition for treating fibromyalgia syndrome. CN 104027742 A. 2014.
   Google Scholar
• Knudsen HD Milkweed seed oil administered to animals. US9265807 B1. 2016.
   Google Scholar
• Pridgen WL Valaciclovir and celecoxib combination therapy for functional somatic syndromes. US 0203783 A1. 2013.
   Google Scholar
• Pridgen WL Aciclovir and meloxicam combination therapy for functional somatic syndromes. US 0203744 A1. 2013.
   Google Scholar
• Pridgen WL Famciclovir and meloxicam combination therapy for functional somatic syndromes. US 0203743 A1. 2013.
   Google Scholar
• Pridgen WL Antiviral compound and cox-2 inhibitor combination therapy for functional somatic syndromes, including combination of famciclovir and celecoxibe. US 0378480 A1. 2014.
   Google Scholar
• Pridgen WL Valaciclovir and meloxicam combination therapy for functional somatic syndromes. US 0011538 A1. 2015.
   Google Scholar
• Sesha R Pharmaceutical compositions for treating pain. WO 063263 A1. 2013.
   Google Scholar
• Roberts MJ, Pedder S Pharmaceutical composition comprising droxidopa for the treatment of fibromyalgia. EP 2468271 B1. 2014.
   Google Scholar
• Jenkins P Compounds and methods for pharmaceutical use. US 0286073 A1. 2010.
   Google Scholar
• Sakai K Method and pharmaceutical composition for treatment of mental disorders. US 0065749 A1. 2011.
   Google Scholar
• Nishioka K, Oka H, Nohara R Pharmaceutical composition for treatment of fibromyalgia. US 20110217387 A1. 2011.
   Google Scholar
• Nishioka K Therapeutic agent for fibromyalgia containing etanercept. US20130108637 A1. 2014.
   Google Scholar
• Ueda H Therapeutic agent for fibromyalgia which comprises donepezil. WO 115083 A1. 2013.
   Google Scholar
• Aung-Din R Topical peripheral neuro-affective (tpna) therapy. US 0165468 A1. 2013.
   Google Scholar
• Katz RS, Leavitt F Methods for treating fibromyalgia. WO 071194 A2. 2014.
   Google Scholar
• Malloy EM Compositions and methods for treatment of fibromyalgia. WO 2016196274 A1. 2016.
   Google Scholar
• Brito RG, Araújo AAS, Quintans JSS, et al. Enhanced analgesic activity by cyclodextrins - a systematic review and meta-analysis. Expert Opin Drug Deliv. 2015;12(10):1677–1688.
   PubMed Web of Science ®Google Scholar
• Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR recommendations for management of fibromyalgia. Ann Rheum Dis. 2017;76(2):318–328. DOI:10.1136/annrheumdis-2017;209724.
   Web of Science ®Google Scholar
• Metyas S, Rezk T, Arkfeld D, et al. The Inflammatory Fibromyalgia. Curr Rheumatol Rev. 2016;12:1-1.
   Google Scholar
• Katz J, Fashler SR, Wicks C, et al. Sensitivity to Pain Traumatization Scale: development, validation, and preliminary findings. J Pain Res. 2017;10:1297–1316.
   PubMedGoogle Scholar
• Ernst E. Herbal medicine in the treatment of rheumatic diseases. Rheum Dis Clin North Am. 2011 Feb;37(1):95–102.
   PubMed Web of Science ®Google Scholar
• Lawson K. Potential drug therapies for the treatment of fibromyalgia. Expert Opin Investig Drugs. 2016 Sep;25(9):1071–1081. DOI:10.1080/13543784.2016.1197906.
   PubMed Web of Science ®Google Scholar